SAN FRANCISCO, CA— EverGene Biosciences, Inc. today announced the appointment of Dr. Sergey Kornilov as Chief Scientific Officer, effective immediately. Dr. Kornilov will lead the company's scientific strategy, overseeing research across the EverSelect™ senescent cell mapping platform, the ChronoSync™ biomarker intelligence system, and the expanding clinical pipeline.
“Sergey brings a rare combination of computational rigor and biological intuition,” said Dr. Marcus Chen, Co-Founder and CEO of EverGene Bio. “His work in precision longevity has fundamentally shaped how we think about the intersection of aging biology and data science. We're thrilled to have him lead our scientific efforts as we advance EVG-001 toward clinical studies.”
“The opportunity to translate computational insight into real therapeutic outcomes is what drew me to EverGene Bio. The EverSelect™ platform represents a genuine paradigm shift in how we identify and eliminate senescent cells — and I believe we're closer to programmable healthspan than most people realize.”
Dr. Kornilov joins EverGene Bio from the intersection of academic research and industry, where he has published extensively on computational approaches to biological aging, multi-omics data integration, and precision medicine frameworks. His research has been cited over 2,000 times and has informed therapeutic strategies at multiple clinical-stage biotechnology companies.
About EverGene Bio
EverGene Biosciences is a precision longevity company developing next-generation senolytic therapeutics. The company's proprietary EverSelect™ platform leverages computational biology and single-cell analytics to identify and selectively eliminate senescent cells with unprecedented specificity. EverGene Bio is headquartered in San Francisco with research operations in South San Francisco, California.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, and actual results may differ materially. No statement in this release should be construed as a guarantee of therapeutic efficacy, regulatory approval, or the continued existence of this company. “Programmable healthspan” is aspirational and not a recognized medical term. Dr. Kornilov's previous work “shaping the future of human health from his LinkedIn feed” refers to thought leadership contributions on social media, not clinical interventions.
Media Contact
EverGene Bio Communications
contact@evergenebio.com